DAX25.239 +0,4%Est505.969 +1,1%MSCI World4.343 -0,1%Top 10 Crypto12,16 -0,2%Nas23.480 -0,4%Bitcoin77.566 -0,6%Euro1,1643 -0,2%Öl62,56 -0,2%Gold4.467 -0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Bayer BAY001 Deutsche Telekom 555750 Novo Nordisk A3EU6F DroneShield A2DMAA Allianz 840400 Siemens Energy ENER6Y RENK RENK73 Amazon 906866 Lufthansa 823212 BASF BASF11 TKMS thyssenkrupp Marine Systems TKMS00 Infineon 623100 Siemens 723610
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX mit Rekord -- Tilray übertrifft Erwartungen -- TUI, Alphabet, BMW, BioNTech, Rheinmetall, TKMS & Co., DroneShield, Glencore, Rio Tinto, Merck & Co. im Fokus
Top News
So entwickeln sich Silberpreis, Erdgaspreis & Co. am Freitagmittag am Rohstoffmarkt So entwickeln sich Silberpreis, Erdgaspreis & Co. am Freitagmittag am Rohstoffmarkt
Trump plant 200 Mrd. USD MBS-Käufe über Fannie Mae und Freddie Mac und die Märkte setzen bereits auf diese Gewinner Trump plant 200 Mrd. USD MBS-Käufe über Fannie Mae und Freddie Mac und die Märkte setzen bereits auf diese Gewinner
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Viatris Aktie

Kaufen
Verkaufen
Viatris Aktien-Sparplan
10,72 EUR -0,10 EUR -0,88 %
STU
12,59 USD +0,14 USD +1,08 %
BTT
Viatris jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.12,32 Mrd. EUR

Div. Rendite3,86%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2QAME

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS92556V1061

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolVTRS

Viatris Aktien News

DatumMeistgelesen
PR NewswireViatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
PR NewswireViatris Provides Pipeline Update on Four Regulatory Milestones
PR NewswireViatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
Wer­bungViatris-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireViatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back
PR NewswireViatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
PR NewswireViatris to Participate in Upcoming Investor Conferences
PR NewswireEuropäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und Medicines for Europe vorges...
PR NewswireEuropean study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for Europe
PR NewswireViatris Recognized as One of the Fortune World's Best Workplaces™ in 2025
PR NewswireViatris Announces Quarterly Dividend
PR NewswireViatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
PR NewswireViatris to Participate in Upcoming Investor Conferences
PR NewswireViatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row
PR NewswireViatris to Report Third Quarter 2025 Financial Results on November 6, 2025
PR NewswireViatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer
PR NewswireViatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.
PR NewswireViatris Announces Quarterly Dividend
PR NewswireViatris Announces Appointment of David Simmons to the Company's Board of Directors
PR NewswireViatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
PR NewswireViatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
PR NewswireViatris Certified as a Great Place to Work® in Canada
PR NewswireViatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
PR NewswireViatris to Report Second Quarter 2025 Financial Results on August 7, 2025
PR NewswireViatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR NewswireVTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireDEADLINE TOMORROW: Berger Montague Advises Viatris (NASDAQ: VTRS) Investors to Inquire About a Securities Fraud Class Action by June 3, 2025
PR NewswireViatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS
PR NewswireViatris Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - VTRS
PR NewswireViatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR NewswireCLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Viatris (NASDAQ: VTRS) Investors to Inquire About a Securities Fraud Class Action by June 3, 2025
PR NewswireViatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada
PR NewswireViatris to Participate in Upcoming Investor Conferences
PR NewswireViatris Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - VTRS
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS
PR NewswireVTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit
PR NewswireVIATRIS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
PR NewswireShareholders that lost money on Viatris Inc.(VTRS) should contact Levi & Korsinsky about pending Class Action - VTRS
PR NewswireViatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR NewswireVTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit

Viatris News

Viatris News: auf dieser Seite finden Sie alle Viatris News und Nachrichten zur Viatris Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Viatris News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Viatris News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.